Globe Roche Logo

cobas® MRSA/SA

MRSA and SA surveillance in under 30 minutes 

The cobas® MRSA/SA assay for use on the cobas® Liat® System allows healthcare professionals to take control of methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus aureus (SA) infections.  Fast, accurate identification, suitable for use in ER, ICU and STAT lab settings, enables rapid response for time-sensitive decolonization and unnecessary isolation of suspected MRSA/SA cases.

Active surveillance to identify carriers with speed and accuracy, using a single nasal swab specimen, brings time saving efficiencies and life-saving answers.

  • Simplified workflow with less than 1 minute hands-on time; no vortex step, no precision pipetting, no result interpretation required
  • High sensitivity and specificity with expanded strain inclusivity for MRSA and SA to detect new and emerging SCCmec subtypes including mecC

 

Intended Use:

The cobas® MRSA/SA Nucleic acid test for use on the cobas® Liat® System is an automated, real-time PCR assay for the rapid in vitro qualitative detection of methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus aureus (SA) DNA from nasal swabs to aid in the identification and control of MRSA and SA infections in healthcare settings. The cobas® MRSA/SA Test is not intended to diagnose, guide or monitor treatment for MRSA or SA infections, or provide results of susceptibility to methicillin. A negative result does not preclude MRSA/SA nasal colonization. Concomitant cultures are necessary to recover organisms for epidemiology typing or for further susceptibility testing.

This product is not registered as an in vitro diagnostic (IVD) in all countries; additional information may be available from your Roche sales representative.

The cobas® Liat® System is commercially available in select markets.

References:

  1. cobas® MRSA/SA [package insert]. Pleasanton, CA: Roche Molecular Systems, Inc., 2017.